TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors influencing Neurogene’s current and future prospects. The completion of enrollment in the Phase 1/2 Rett ‘401 trial, along with the anticipated updated efficacy and safety data in the second half of 2025, demonstrates progress in their clinical development. The absence of adverse effects such as HLH/hyperinflammatory syndrome at the current dose level further supports the potential of their treatment.
Additionally, Neurogene’s financial position appears stable, with a cash runway expected to last into early 2028, providing a solid foundation for ongoing and future trials. The initiation of activities to transition the Phase 1/2 study into the registrational ‘Embolden’ trial, with an expanded sample size, suggests a strategic approach to gathering comprehensive data for potential full approval. These elements collectively contribute to a positive outlook for Neurogene’s stock, justifying the Buy rating.
Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and Alnylam Pharma. According to TipRanks, Baral has an average return of 12.5% and a 48.49% success rate on recommended stocks.